Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Interest Expenses (2024 - 2025)

Indivior Pharmaceuticals has reported Interest Expenses over the past 2 years, most recently at $6.0 million for Q4 2025.

  • Quarterly results put Interest Expenses at $6.0 million for Q4 2025, down 53.85% from a year ago — trailing twelve months through Dec 2025 was $45.0 million (up 7.14% YoY), and the annual figure for FY2025 was $45.0 million, up 9.76%.
  • Interest Expenses for Q4 2025 was $6.0 million at Indivior Pharmaceuticals, down from $12.0 million in the prior quarter.
  • Over the last five years, Interest Expenses for INDV hit a ceiling of $15.0 million in Q2 2025 and a floor of $6.0 million in Q4 2025.